Coriolis Pharma, a globally operating contract research and development organization specializing in biopharmaceutical formulation, announced a $10 million investment to establish a state-of-the-art research laboratory in Morrisville, North Carolina. The facility represents the company's first U.S. laboratory and strategic expansion into the North American market.
The new 13,000 square foot laboratory will be located at Spark LS, an innovative life science campus in the Research Triangle Park region, and is scheduled to commence operations in the first quarter of 2026. The facility will create 50 jobs and serve as Coriolis Pharma's U.S. headquarters.
Core Services and Capabilities
The North Carolina laboratory will initially deliver particle identification services, followed by formulation development and lyophilization capabilities. These services will be seamlessly integrated with Coriolis Pharma's global scientific and operational network, maintaining close collaboration with the company's headquarters in Martinsried-Munich, Germany.
"With our future presence in North Carolina, we will be able to serve our North American clients even better, offering our core services quickly and efficiently on site," said Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma. "The decisive factor in our choice of location was the strong scientific fit with the North Carolina ecosystem, a global biotechnology center of excellence."
Technology Integration and Innovation
The facility is designed to support future innovation, including the adoption of advanced digital and in-silico technologies. This technological integration reinforces Coriolis Pharma's vision to accelerate and de-risk biopharmaceutical development across various therapeutic modalities.
Coriolis Pharma brings cross-modality formulation expertise, scientific depth, and advanced analytical capabilities to the pharmaceutical and biotech industry. The company focuses on liquid and lyophilized drug products, offering tailored solutions from early development stages to market approval.
Strategic Location Benefits
The laboratory's location at Spark LS provides access to the region's largest mixed-use life science and innovation campus, featuring 1.5 million square feet of laboratory and biomanufacturing space across approximately 108 acres. The campus offers world-class amenities including restaurants, conference facilities, fitness centers, and collaborative spaces.
"Coriolis Pharma's decision to establish their U.S. headquarters and first U.S. lab here at Spark is a testament to the innovative environment we're cultivating and the immense potential within the region's burgeoning biotech sector," said Jeff Sheehan, Managing Partner at Trinity Capital, Spark's developer.
Implementation Timeline
Coriolis Pharma will advance the build-out of the North Carolina laboratory in the coming months and begin hiring its first new employees. The investment underscores the company's strategic commitment to expanding its global innovation footprint and accelerating digital transformation in drug development.
The expansion positions Coriolis Pharma to better serve North American clients while maintaining its mission to convert cutting-edge biomolecules into life-saving therapies through scientific excellence and innovative analytical methods.
